Patent application number | Description | Published |
20130074907 | MONOLITHIC InGaN SOLAR CELL POWER GENERATION WITH INTEGRATED EFFICIENT SWITCHING DC-DC VOLTAGE CONVERTOR - A single monolithic integrated circuit ( | 03-28-2013 |
20130088392 | DISTRIBUTED POWER CONDITIONING WITH DC-DC CONVERTERS IMPLEMENTED IN HETEROGENEOUS INTEGRATED CIRCUIT - A flat panel active electronically scanned array (AESA) ( | 04-11-2013 |
20140028387 | MONOLITHIC INTEGRATED CIRCUIT CHIP INTEGRATING MULTIPLE DEVICES - A monolithic integrated circuit (IC) chip containing a plurality of transistors, including: a substrate; a first transistor on the substrate; and a second transistor integrally formed on the substrate with the first transistor, the second transistor having a different structure than the first transistor, wherein the first transistor includes a first material system and the second transistor includes a second material system different from the first material system. The monolithic IC chip may further include a third transistor integrally formed on the substrate with the first and second transistors. The first transistor may include gallium nitride (GaN) and the second and third transistors may include silicon carbide (SiC). | 01-30-2014 |
20140072136 | APPARATUS FOR MONITORING THE CONDITION OF AN OPERATOR AND RELATED SYSTEM AND METHOD - An apparatus includes a headset having one or more speaker units. Each speaker unit is configured to provide audio signals to an operator. Each speaker unit includes an ear cuff configured to contact the operator's head. The headset further includes multiple sensors configured to measure one or more characteristics associated with the operator. At least one of the sensors is embedded within at least one ear cuff of at least one speaker unit. The sensors could include an electrocardiography electrode, a skin conductivity probe, pulse oximetry light emitting diodes and photodetectors, an accelerometer, a gyroscope, or a temperature sensor. The apparatus could also include a processing unit configured to analyze audio signals captured by a microphone unit of the headset to identify respiration by the operator or at least one voice characteristic of the operator. | 03-13-2014 |
20150130657 | HIGH SPEED, HIGH EFFICIENCY, HIGH POWER RF PULSE MODULATING INTEGRATED SWITCH - Embodiments of a drain modulator that uses high power switch sensing to control active pulldown are generally described herein. In some embodiments, a logic and sense module is arranged to receive a control signal for controlling an on and an off state of an input of a switch to turn a high power voltage at an output of the switch on and off. A pullup module and a pulldown module are coupled to the input of the switch. An active pulldown module coupled to the output of the switch. The logic and sense module monitors the input to the switch and activates the active pulldown module to drain the output of the switch to a zero voltage when the input of the switch transitions to the off state. | 05-14-2015 |
Patent application number | Description | Published |
20120088747 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF - Compounds, compositions and methods for treating GHS-R mediated disorders are described herein. | 04-12-2012 |
20120122849 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER - Compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of cancer. | 05-17-2012 |
20120122885 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 05-17-2012 |
20130035329 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. | 02-07-2013 |
20130190287 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. | 07-25-2013 |
20140011804 | BICYCLIC PKM2 ACTIVATORS - Compounds and compositions comprising compounds including formula (I) that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer. | 01-09-2014 |
20140073625 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS - Compounds of general Formula (I), and compositions comprising compounds of general formula I that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 03-13-2014 |
20140142081 | COMPOUNDS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 05-22-2014 |
20140142146 | COMPOUNDS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 05-22-2014 |
20140206673 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds of formula (I), wherein X, Y, Z, W, V, R | 07-24-2014 |
20140213580 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds. | 07-31-2014 |
20140249196 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 09-04-2014 |
20140288090 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 09-25-2014 |
20140323467 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 10-30-2014 |
20140323729 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 10-30-2014 |
20150087600 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here. | 03-26-2015 |
20150141464 | N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5 -mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 05-21-2015 |
20150183760 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 07-02-2015 |
20150291576 | COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided. | 10-15-2015 |
20150299115 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL). | 10-22-2015 |
20150299152 | GLUTAMASE INHIBITORS AND METHOD OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 10-22-2015 |
20150307473 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS - Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases. | 10-29-2015 |
Patent application number | Description | Published |
20110282418 | METHODS AND DEVICES FOR COOLING SPINAL TISSUE - Methods, systems, and devices are disclosed for cooling tissue, and in particular for applying therapeutic hypothermia to the spinal canal, tissue disposed within the spinal canal, and nerve roots extending from the spinal canal. Bone screws, intervertebral implants, stabilization rods, spinous process spacers, and other devices are described which define a chamber through which a chilled fluid, expandable gas, or other coolant means can be circulated, delivered, or activated to cool adjacent tissue. The degree of cooling can be regulated using a controller, which can be configured to increase or decrease the cooling effect based on any of a variety of measured or predicted physiological or thermodynamic properties. Methods are disclosed for implanting cooling instruments and for carrying out various treatment regimens that involve cooling tissue using such instruments. | 11-17-2011 |
20130281995 | METHODS AND DEVICES FOR COOLING SPINAL TISSUE - Methods, systems, and devices are disclosed for cooling tissue, and in particular for applying therapeutic hypothermia to the spinal canal, tissue disposed within the spinal canal, and nerve roots extending from the spinal canal. Bone screws, intervertebral implants, stabilization rods, spinous process spacers, and other devices are described which define a chamber through which a chilled fluid, expandable gas, or other coolant means can be circulated, delivered, or activated to cool adjacent tissue. The degree of cooling can be regulated using a controller, which can be configured to increase or decrease the cooling effect based on any of a variety of measured or predicted physiological or thermodynamic properties. Methods are disclosed for implanting cooling instruments and for carrying out various treatment regimens that involve cooling tissue using such instruments. | 10-24-2013 |
20140358183 | METHODS AND DEVICES FOR COOLING SPINAL TISSUE - Methods, systems, and devices are disclosed for cooling tissue, and in particular for applying therapeutic hypothermia to the spinal canal, tissue disposed within the spinal canal, and nerve roots extending from the spinal canal. Bone screws, intervertebral implants, stabilization rods, spinous process spacers, and other devices are described which define a chamber through which a chilled fluid, expandable gas, or other coolant means can be circulated, delivered, or activated to cool adjacent tissue. The degree of cooling can be regulated using a controller, which can be configured to increase or decrease the cooling effect based on any of a variety of measured or predicted physiological or thermodynamic properties. Methods are disclosed for implanting cooling instruments and for carrying out various treatment regimens that involve cooling tissue using such instruments. | 12-04-2014 |
Patent application number | Description | Published |
20110244092 | Protein product and process for making injectable protein product - Moisture is retained in cooked or thawed food by adding to the food an aqueous suspension of animal muscle protein obtained from animal muscle tissue. The aqueous suspension is obtained by mixing comminuted animal muscle tissue with a food grade acid to form an aqueous acidic solution of animal muscle protein. The acidic solution is mixed with a food grade base to precipitate the protein in an aqueous composition. The precipitated protein then is comminuted to form an aqueous suspension of comminuted animal muscle protein. | 10-06-2011 |
20110244093 | Protein product and process for preparing injectable protein product - Moisture is retained in cooked or thawed food by adding to the food an aqueous suspension of animal muscle protein obtained from animal muscle tissue. The aqueous suspension is obtained by mixing comminuted animal muscle tissue with a food grade base to form an aqueous basic solution of animal muscle protein. The basic solution is mixed with a food grade acid to precipitate the protein in an aqueous composition. The precipitated protein then is comminuted to form an aqueous suspension of comminuted animal muscle protein. | 10-06-2011 |
20120082767 | Process for reducing oil and fat in cooked food with pea protein - A process for cooking a food in oil and/or fat is provided. A dry pea protein mixture or an aqueous pea protein is added to a food prior to cooking. The amount of oil and/or fat absorbed by the food during cooking is substantially reduced. | 04-05-2012 |
20120171345 | Process for isolating a protein composition and a fat composition from mechanically deboned poultry - A protein fraction and an oxidation stable fat fraction are recovered from poultry containing fat, bone and protein. The poultry is comminuted, mixed with a food grade acid at pH 3.6 to 4.4 to form a liquid protein fraction and a solid fat fraction. The liquid fraction is mixed with a food grade alkali to precipitate the protein. | 07-05-2012 |
20140023759 | PROTEIN PRODUCT AND PROCESS FOR PREPARING INJECTABLE PROTEIN PRODUCT - Moisture is retained in cooked or thawed food by adding to the food an aqueous suspension of animal muscle protein obtained from animal muscle tissue. The aqueous suspension is obtained by mixing comminuted animal muscle tissue with a food grade base to form an aqueous basic solution of animal muscle protein. The basic solution is mixed with a food grade acid to precipitate the protein in an aqueous composition. The precipitated protein then is comminuted to form an aqueous suspension of comminuted animal muscle protein. | 01-23-2014 |
20140044859 | PRODUCT AND PROCESS FOR REDUCING OIL AND FAT CONTENT IN COOKED FOOD WITH ANIMAL MUSCLE PROTEIN IN SUSPENSION - A product for cooking a food in oil and/or fat is provided. An adjusted pH protein suspension is produced in an aqueous or dry form and comprises myofibrillar proteins and sarcoplasmic proteins substantially free of myofibrils and sarcomeres. The amount of oil and/or fat absorbed by the food during cooking is substantially reduced while the food retains its color and taste. | 02-13-2014 |
20150264971 | Process fo Reducing Oil and Fat Content in Cooked Food with Pea Protein - A process for cooking a food in oil and/or fat is provided. A dry pea protein mixture or an aqueous pea protein is added to a food prior to cooking. The amount of oil and/or fat absorbed by the food during cooking is substantially reduced. | 09-24-2015 |